Referencias:

• Camm, A.J., Kirchhof, P., Lip, G.Y., Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) (2010) Eur Heart J, 31 (19), pp. 2369-2429. , European Heart Rhythm Association; European Association for Cardio Thoracic Surgery
• Pisters, R., Nieuwlaat, R., Prins, M.H., Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: The Euro Heart Survey (2012) Europace, 14 (5), pp. 666-674. , Euro Heart Survey Investigators
• Camm, A.J., Lip, G.Y., De Caterina, R., 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association (2012) Europace, 14 (10), pp. 1385-1413. , ESC Committee for Practice Guidelines- CPG; Document Reviewers
• Fedida, D., Vernakalant (RSD1235): A novel, atrial-selective antifibrillatory agent (2007) Expert Opin Investig Drugs, 16 (4), pp. 519-532
• Wettwer, E., Christ, T., Endig, S., The new antiarrhythmic drug vernakalant: Ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation (2013) Cardiovasc Res, 98 (1), pp. 145-154
• Dobrev, D., Nattel, S., New antiarrhythmic drugs for treatment of atrial fibrillation (2010) Lancet, 375 (9721), pp. 1212-1223
• Fedida, D., Orth, P.M., Chen, J.Y., The mechanism of atrial antiarrhythmic action of RSD1235 (2005) J Cardiovasc Electrophysiol, 16 (11), pp. 1227-1238
• Orth, P.M., Hesketh, J.C., Mak, C.K., RSD1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agents (2006) Cardiovasc Res, 70 (3), pp. 486-496
• Comtois, P., Sakabe, M., Vigmond, E.J., Mechanisms of atrial fibrillation termination by rapidly unbinding Na+ channel blockers: Insights from mathematical models and experimental correlates (2008) Am J Physiol Heart Circ Physiol, 295 (4), pp. H1489-H1504
• Antzelevitch, C., Burashnikov, A., Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation (2010) Ann N y Acad Sci, 1188 (1), pp. 78-86
• Burashnikov, A., Di Diego, J.M., Zygmunt, A.C., Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: Differences in sodium channel inactivation between atria and ventricles and the role of ranolazine (2007) Circulation, 116 (13), pp. 1449-1457
• Burashnikov, A., Di Diego, J.M., Sicouri, S., Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation (2008) Heart Rhythm, 5 (12), pp. 1735-1742
• Burashnikov, A., Pourrier, M., Gibson, J.K., Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: Comparison with ranolazine and dl-sotalol (2012) Circ Arrhythm Electrophysiol, 5 (2), pp. 400-408
• Suzuki, T., Morishima, M., Kato, S., Atrial selectivity in Na+ channel blockade by acute amiodarone (2013) Cardiovasc Res, 98 (1), pp. 136-144
• Roy, D., Rowe, B.H., Stiell, I.G., A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation (2004) J Am Coll Cardiol, 44 (12), pp. 2355-2361. , CRAFT Investigators
• Roy, D., Pratt, C.M., Torp-Pedersen, C., Vernakalant hydrochloride for rapid conversion of atrial fibrillation: A phase 3, randomized, placebo-controlled trial (2008) Circulation, 117 (12), pp. 1518-1525. , Atrial Arrhythmia Conversion Trial Investigators
• Kowey, P.R., Dorian, P., Mitchell, L.B., Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: A randomized, doubleblind, placebo-controlled trial (2009) Circ Arrhythm Electrophysiol, 2 (6), pp. 652-659. , Atrial Arrhythmia Conversion Trial Investigators
• Pratt, C.M., Roy, D., Torp-Pedersen, C., Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation (2010) Am J Cardiol, 106 (9), pp. 1277-1283. , Atrial Arrhythmia Conversion Trial (ACT-III) Investigators
• Stiell, I.G., Roos, J.S., Kavanagh, K.M., A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm (2010) Am Heart J, 159 (6), pp. 1095-1101
• Camm, A.J., Capucci, A., Hohnloser, S.H., A randomized active controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation (2011) J Am Coll Cardiol, 57 (3), pp. 313-321. , AVRO Investigators
• Camm, A.J., Toft, E., Torp-Pedersen, C., Efficacy and safety of vernakalant in patients with atrial flutter: A randomized, doubleblind, placebo-controlled trial (2012) Europace, 14 (6), pp. 804-809. , Scene 2 Investigators
• Conde, D., Costabel, J.P., Aragon, M., Propafenone versus vernakalant for conversion of recent-onset atrial fibrillation (2013) Cardiovasc Ther, 31 (6), pp. 377-380
• Conde, D., Costabel, J.P., Caro, M., Flecainide versus vernakalant for conversion of recent onset atrial fibrillation (2013) Int J Cardiol, 168, pp. 2423-2425
• Conde, D., Costabel, J.P., Alves De Lima, A., Recent-onset atrial fibrillation in patients with left ventricular dysfunction: Amiodarone orvernakalant? (2013) Can J Cardiol, 29, p. 1330
• Conde, D., Lalor, N., Rodriguez, L., Vernakalant versus electrical cardioversion in recent-onset atrial fibrillation (2013) Int J Cardiol, 168, pp. 4431-4432
• (2010) European Medicines Agency (EMA) Assessment Report for Brinavess, , http://www.ema.europa.eu/docs/en_GB/document_library /EPAR_-_Public_assessment_report/human/001215/WC500097150.pdf, London: EMA;. (Accessed April 3, 2013). Available from
• Savelieva, I., Graydon, R., Camm, A.J., Pharmacological cardioversion of atrial fibrillation with vernakalant: Evidence in support of the ESC Guidelines (2014) Europace, 16 (2), pp. 162-173

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------